Literature DB >> 17298771

Emergency treatment of movement disorders.

Shu-Ching Hu1, Steven J Frucht.   

Abstract

Movement disorder emergencies occur in both hypokinetic and hyperkinetic patients. Prompt recognition of these emergencies is crucial, and diagnosis is based on history and phenomenology. Supportive and temporizing measures must be implemented immediately before disease-specific therapy is begun. For neuroleptic malignant syndrome and related conditions, we recommend a three-tier approach depending on severity, starting with benzodiazepines, dopamine agonists or levodopa, and dantrolene or electroconvulsive therapy. Methylprednisolone pulse therapy also is beneficial for neuroleptic malignant syndrome due to abrupt medication withdrawal in patients with Parkinson's disease. In treatment of other acute antidopaminergic-induced emergencies, anticholinergics usually suffice. To manage airway obstruction related to movement disorders, we rely on laryngoscopic evaluation to determine whether noninvasive or invasive interventions are needed. Hyperkinetic emergencies are treated individually based on the type of abnormal movements. If an antidopaminergic is needed, we prefer a dopamine depletor to a dopamine receptor blocker because of the risk of tardive syndromes with the latter. When focal hyperkinetic movements dominate the picture, botulinum toxin injection is a useful adjunct to medications.

Entities:  

Year:  2007        PMID: 17298771     DOI: 10.1007/s11940-007-0036-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  16 in total

1.  Myoclonus.

Authors:  Melissa J Nirenberg; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.598

2.  Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy.

Authors:  E Isozaki; A Naito; S Horiguchi; R Kawamura; T Hayashida; H Tanabe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.

Authors:  C Marras; D Andrews; E Sime; A E Lang
Journal:  Neurology       Date:  2001-03-13       Impact factor: 9.910

4.  Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.

Authors:  G A Grillone; A Blitzer; M F Brin; D J Annino; M H Saint-Hilaire
Journal:  Laryngoscope       Date:  1994-01       Impact factor: 3.325

5.  The effects of clonazepam and vigabatrin in hyperekplexia.

Authors:  M A Tijssen; H C Schoemaker; P J Edelbroek; R A Roos; A F Cohen; J G van Dijk
Journal:  J Neurol Sci       Date:  1997-07       Impact factor: 3.181

6.  Status dystonicus: the syndrome and its management.

Authors:  H Manji; R S Howard; D H Miller; N P Hirsch; L Carr; K Bhatia; N Quinn; C D Marsden; K Bahtia
Journal:  Brain       Date:  1998-02       Impact factor: 13.501

7.  Botulinum toxin in the treatment of tics.

Authors:  C H Kwak; P A Hanna; J Jankovic
Journal:  Arch Neurol       Date:  2000-08

8.  A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor.

Authors:  S J Frucht; W C Houghton; Y Bordelon; P E Greene; E D Louis
Journal:  Neurology       Date:  2005-12-27       Impact factor: 9.910

9.  Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.

Authors:  W R Gibb; D N Griffith
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

10.  Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.

Authors:  Michael Poyurovsky; Artashes Pashinian; Ronit Weizman; Camil Fuchs; Abraham Weizman
Journal:  Biol Psychiatry       Date:  2006-02-21       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.